Hossein Montakhab-Yeganeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hossein Montakhab-Yeganeh has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alireza Badirzadeh
Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
4 shared publications - Sima Rafati
Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran
4 shared publications Farnaz Zahedifard
Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran
2 shared publicationsNegar Seyed
Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran
2 shared publications- Safoora Gharibzadeh
Leicester Real World Evidence Unit Diabetes Research Centre, Leicester General Hospital, University of Leicester Leicester UK
2 shared publications Tahereh Taheri
Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran
2 shared publications
Latest Publications
- 25 November 2018
- Published by Wiley in Parasite Immunology
- Vol. 41 (1) , e12605
Sambucus ebulus extract stimulates cellular responses in cutaneous leishmaniasis
Summary: This is the first study aiming to determine the therapeutic effects of the Sambucus ebulus aquatic extract as an antileishmanial herbal drug and evaluate the immune responses in Leishmania major major infected BALB/c mice. The antileishmanial activity of S ebulus aquatic extract was evaluated using MTT test as well as parasite rescue and transformation assay. Footpad swelling and parasite load of infected mice were measured by several techniques. The immune responses were evaluated by measuring the levels of IFN‐γ, IL‐4, nitric oxide and arginase. The results indicated that S. ebulus can significantly decrease L. major promastigotes and amastigotes viability, but it was not toxic to macrophages. The lesion size, parasite burden and the level of ARG decreased in the treated infected mice, while the IFN‐γ‐to‐IL‐4 ratio and the level of NO increased significantly. Altogether, the S. ebulus extract is an effective compound for killing Leishmania parasite without excessive toxicity to the host cells and can cure the CL by switching the host immune responses towards Th1 response. Thus, it may be a perfect therapeutic option for CL treatment.
- 25 November 2018
- Published by Wiley in Parasite Immunology
- Vol. 41 (1) , e12605
Sambucus ebulus extract stimulates cellular responses in cutaneous leishmaniasis
Summary: This is the first study aiming to determine the therapeutic effects of the Sambucus ebulus aquatic extract as an antileishmanial herbal drug and evaluate the immune responses in Leishmania major major infected BALB/c mice. The antileishmanial activity of S ebulus aquatic extract was evaluated using MTT test as well as parasite rescue and transformation assay. Footpad swelling and parasite load of infected mice were measured by several techniques. The immune responses were evaluated by measuring the levels of IFN‐γ, IL‐4, nitric oxide and arginase. The results indicated that S. ebulus can significantly decrease L. major promastigotes and amastigotes viability, but it was not toxic to macrophages. The lesion size, parasite burden and the level of ARG decreased in the treated infected mice, while the IFN‐γ‐to‐IL‐4 ratio and the level of NO increased significantly. Altogether, the S. ebulus extract is an effective compound for killing Leishmania parasite without excessive toxicity to the host cells and can cure the CL by switching the host immune responses towards Th1 response. Thus, it may be a perfect therapeutic option for CL treatment.
- Open Access
- 28 August 2018
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 17, 864-870
Effect of elaidic acid on ABCA1 expression in RAW 264.7 cells. Is it through PPAR-gamma?
In recent years, Trans Fatty Acids have shown a strong correlation with cardiovascular disease. However, the mechanisms explaining their atherogenicity are still unclear. ABCA1, which is involved in the reverse cholesterol transport pathway, has been considered as a new therapeutic target for cardiovascular disease. In vitro studies of the effects of PPAR-γ on lipid homeostasis in macrophage cells suggested a role for PPAR-γ in the regulation of ABCA1-dependent cholesterol efflux to apoA-I pathway. Thus, in this study we examined the effect of elaidic acid (EA) as the most abundant TFA on expression of ABCA1 and PPAR-γ in RAW 264.7 mouse macrophage cell line. Accordingly, after determining appropriate concentrations of EA using MTT, RAW 264.7 cells were treated with different concentrations of EA, and at the end, gene expression was assayed by Real-Time PCR. Our results shown that the expression of ABCA1 decreased in the treated group in comparison with the control group by 1.7, 2.3, and 5.1 fold, after 12 h treatment for 0.5, 1, and 2 mM EA concentration respectively. In addition, after 24 h treatment with EA, the rate of decreasing ABCA1 expression was 2.1, 2.6, 5.7 fold, respectively (P < 0.01). However, EA had no significant effect on PPAR-γ mRNA expression. Therefore, it could be concluded that the atherogenic effect of EA may be mediated by reducing ABCA1 expression in RAW 264.7 cells; however, this reduction has not mediated through altering PPAR-γ expression.
- 28 August 2018
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 17, 864-870
Open AccessEffect of elaidic acid on ABCA1 expression in RAW 264.7 cells. Is it through PPAR-gamma?
In recent years, Trans Fatty Acids have shown a strong correlation with cardiovascular disease. However, the mechanisms explaining their atherogenicity are still unclear. ABCA1, which is involved in the reverse cholesterol transport pathway, has been considered as a new therapeutic target for cardiovascular disease. In vitro studies of the effects of PPAR-γ on lipid homeostasis in macrophage cells suggested a role for PPAR-γ in the regulation of ABCA1-dependent cholesterol efflux to apoA-I pathway. Thus, in this study we examined the effect of elaidic acid (EA) as the most abundant TFA on expression of ABCA1 and PPAR-γ in RAW 264.7 mouse macrophage cell line. Accordingly, after determining appropriate concentrations of EA using MTT, RAW 264.7 cells were treated with different concentrations of EA, and at the end, gene expression was assayed by Real-Time PCR. Our results shown that the expression of ABCA1 decreased in the treated group in comparison with the control group by 1.7, 2.3, and 5.1 fold, after 12 h treatment for 0.5, 1, and 2 mM EA concentration respectively. In addition, after 24 h treatment with EA, the rate of decreasing ABCA1 expression was 2.1, 2.6, 5.7 fold, respectively (P < 0.01). However, EA had no significant effect on PPAR-γ mRNA expression. Therefore, it could be concluded that the atherogenic effect of EA may be mediated by reducing ABCA1 expression in RAW 264.7 cells; however, this reduction has not mediated through altering PPAR-γ expression.
- Open Access
- 18 December 2017
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 11 (12) , e0006123
Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice
Human Neutrophil Peptide-1 (HNP1) produced by neutrophils, is a well-known antimicrobial peptide which plays a role both in innate as well as in adaptive immunity and is under intensive investigation as a potential therapeutic agent. Previous in vitro experiments have indicated the leishmaniacidal effect of recombinant HNP1 on Leishmania major (L. major) promastigotes and amastigotes. In the current study, we further extended the idea to explore the remedial effect of HNP1 in the two modalities of peptide therapy (folded HNP1) and gene therapy in L. major infected BALB/c mice. To this end, mice in five different groups received synthetic folded HNP1 (G1), pcDNA-HNP1-EGFP (G2), pcDNA-EGFP (G3), Amphotericin B (G4) and PBS (G5), which was started three weeks after infection for three consecutive weeks. Footpad swelling was monitored weekly and a day after the therapy ended, IFN-γ, IL-4, IL-10, IL-6 and nitric oxide produced by splenocytes were analyzed together with the parasite load in draining lymph nodes. Arginase activity and dermal histopathological changes were also analyzed in the infected footpads. We demonstrated that both therapeutic approaches effectively induced Th1 polarization and restricted parasite burden. It can control disease progression in contrast to non-treated groups. However, pcDNA-HNP1-EGFP is more promising in respect to parasite control than folded HNP1, but less effective than AmB treatment. We concluded with the call for a future approach, that is, a DNA-based expression of HNP1 combined with AmB as it can improve the leishmaniacidal efficacy. The outbreak level) of cutaneous leishmaniasis is approximated between one and 1.5 million individuals per year. Owning to several disadvantages of current therapies, special attention to expand novel and efficient therapies has been demanded. Among Anti-Microbial Peptides (AMPs), Human Neutrophil Peptide-1 (HNP1) is one of the most potential defensins. Our promising in vitro experiments have shown the leishmaniacidal effect of recombinant HNP1. Here, we displayed the remedial effect of HNP1 in two approaches including peptide therapy and gene therapy in susceptible mice infected with L. major. Our investigation showed that although both approaches could decrease the parasite load and induce Th1 immune response compared to the control group, pcDNA-HNP1-EGFP has a better effect compared to the folded HNP1. Hence, immunotherapy by HNP1 can help elicit proper immunity despite the direct effect on promastigotes and amastigotes forms of parasite.
- 18 December 2017
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 11 (12) , e0006123
Open AccessHuman Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice
Human Neutrophil Peptide-1 (HNP1) produced by neutrophils, is a well-known antimicrobial peptide which plays a role both in innate as well as in adaptive immunity and is under intensive investigation as a potential therapeutic agent. Previous in vitro experiments have indicated the leishmaniacidal effect of recombinant HNP1 on Leishmania major (L. major) promastigotes and amastigotes. In the current study, we further extended the idea to explore the remedial effect of HNP1 in the two modalities of peptide therapy (folded HNP1) and gene therapy in L. major infected BALB/c mice. To this end, mice in five different groups received synthetic folded HNP1 (G1), pcDNA-HNP1-EGFP (G2), pcDNA-EGFP (G3), Amphotericin B (G4) and PBS (G5), which was started three weeks after infection for three consecutive weeks. Footpad swelling was monitored weekly and a day after the therapy ended, IFN-γ, IL-4, IL-10, IL-6 and nitric oxide produced by splenocytes were analyzed together with the parasite load in draining lymph nodes. Arginase activity and dermal histopathological changes were also analyzed in the infected footpads. We demonstrated that both therapeutic approaches effectively induced Th1 polarization and restricted parasite burden. It can control disease progression in contrast to non-treated groups. However, pcDNA-HNP1-EGFP is more promising in respect to parasite control than folded HNP1, but less effective than AmB treatment. We concluded with the call for a future approach, that is, a DNA-based expression of HNP1 combined with AmB as it can improve the leishmaniacidal efficacy. The outbreak level) of cutaneous leishmaniasis is approximated between one and 1.5 million individuals per year. Owning to several disadvantages of current therapies, special attention to expand novel and efficient therapies has been demanded. Among Anti-Microbial Peptides (AMPs), Human Neutrophil Peptide-1 (HNP1) is one of the most potential defensins. Our promising in vitro experiments have shown the leishmaniacidal effect of recombinant HNP1. Here, we displayed the remedial effect of HNP1 in two approaches including peptide therapy and gene therapy in susceptible mice infected with L. major. Our investigation showed that although both approaches could decrease the parasite load and induce Th1 immune response compared to the control group, pcDNA-HNP1-EGFP has a better effect compared to the folded HNP1. Hence, immunotherapy by HNP1 can help elicit proper immunity despite the direct effect on promastigotes and amastigotes forms of parasite.
- 16 October 2017
- Published by Taylor & Francis in Immunotherapy
- Vol. 9 (13) , 1089-1102
Live Leishmania tarentolae Secreting HNP1 as an Immunotherapeutic Tool Against Leishmania Infection in BALB/c Mice
Aim: Several disadvantages about chemotherapy for leishmaniasis has reinforced discovery of novel therapeutic agents especially immunotherapeutics. HNP1, as a member of the mammalian antimicrobial peptides family, is an attractive molecule due to its broad functional spectrum. Here, the in vivo potency of HNP1 in transgenic Leishmania tarentolae as an immunotherapy tool against Leishmania major-infected BALB/c mice was examined. Methods & results: 3 weeks after infection with L. major, the treatment effect of L. tarentolae-HNP1-EGFP was pursued. The results were promising in respect to parasite load control and Th1 immune response polarization compared with controls. Conclusion: Immunotherapy by live L. tarentolae secreting HNP1 can elicit cellular immune response in a susceptible mouse model in order to control L. major infection.
- 16 October 2017
- Published by Taylor & Francis in Immunotherapy
- Vol. 9 (13) , 1089-1102
Live Leishmania tarentolae Secreting HNP1 as an Immunotherapeutic Tool Against Leishmania Infection in BALB/c Mice
Aim: Several disadvantages about chemotherapy for leishmaniasis has reinforced discovery of novel therapeutic agents especially immunotherapeutics. HNP1, as a member of the mammalian antimicrobial peptides family, is an attractive molecule due to its broad functional spectrum. Here, the in vivo potency of HNP1 in transgenic Leishmania tarentolae as an immunotherapy tool against Leishmania major-infected BALB/c mice was examined. Methods & results: 3 weeks after infection with L. major, the treatment effect of L. tarentolae-HNP1-EGFP was pursued. The results were promising in respect to parasite load control and Th1 immune response polarization compared with controls. Conclusion: Immunotherapy by live L. tarentolae secreting HNP1 can elicit cellular immune response in a susceptible mouse model in order to control L. major infection.
- 20 September 2017
- Published by Wiley in Parasite Immunology
- Vol. 39 (10)
Leishmania tarentolae expressing CXCL‐10 as an efficient immunotherapy approach against Leishmania major‐infected BALB/c mice
Summary: Recent findings have demonstrated the suitability of interferon‐gamma‐induced protein 10 (IP‐10) or CXCL‐10 as an immunotherapy tool in treatment of leishmaniasis. This chemokine can overcome Leishmania (L.) infection through inducing nitric oxide (NO) production for parasite elimination. This study was undertaken to investigate the therapeutic effects of recombinant Leishmania tarentolae expressing CXCL‐10 and an expression vector encoding CXCL‐10 (pcDNA‐CXCL‐10‐EGFP) in a model of BALB/c mice susceptible to infection by Leishmania major. The outcome of intervention was examined at 3 weeks post‐treatment by evaluating the parameters of parasite burden (PB), arginase activity, NO and various cytokines such as IFN‐γ, IL‐4, IL‐6 and IL‐10. The results have shown that despite the efficacy of CXCL‐10 expression vector as gene therapy, the live therapy strategy using L. tarentolae expressing CXCL‐10 was more effective in terms of decreasing PB. Nitric oxide production increased, especially in the live therapy approaches. Arginase activity also decreased in all regimens, which demonstrates the potency of the treatment. The overall cytokine production shifted in favour of Th1 responses in the treated mice. Altogether, recombinant L. tarentolae expressing CXCL‐10 represents a promising therapeutic strategy to improve treatment of cutaneous leishmaniasis.
- 20 September 2017
- Published by Wiley in Parasite Immunology
- Vol. 39 (10)
Leishmania tarentolae expressing CXCL‐10 as an efficient immunotherapy approach against Leishmania major‐infected BALB/c mice
Summary: Recent findings have demonstrated the suitability of interferon‐gamma‐induced protein 10 (IP‐10) or CXCL‐10 as an immunotherapy tool in treatment of leishmaniasis. This chemokine can overcome Leishmania (L.) infection through inducing nitric oxide (NO) production for parasite elimination. This study was undertaken to investigate the therapeutic effects of recombinant Leishmania tarentolae expressing CXCL‐10 and an expression vector encoding CXCL‐10 (pcDNA‐CXCL‐10‐EGFP) in a model of BALB/c mice susceptible to infection by Leishmania major. The outcome of intervention was examined at 3 weeks post‐treatment by evaluating the parameters of parasite burden (PB), arginase activity, NO and various cytokines such as IFN‐γ, IL‐4, IL‐6 and IL‐10. The results have shown that despite the efficacy of CXCL‐10 expression vector as gene therapy, the live therapy strategy using L. tarentolae expressing CXCL‐10 was more effective in terms of decreasing PB. Nitric oxide production increased, especially in the live therapy approaches. Arginase activity also decreased in all regimens, which demonstrates the potency of the treatment. The overall cytokine production shifted in favour of Th1 responses in the treated mice. Altogether, recombinant L. tarentolae expressing CXCL‐10 represents a promising therapeutic strategy to improve treatment of cutaneous leishmaniasis.
- 21 July 2017
- Published by Wiley in Parasite Immunology
- Vol. 39 (9)
Arginase activity ofLeishmaniaisolated from patients with cutaneous leishmaniasis
Summary: Cutaneous leishmaniasis (CL) is one of the most important vector‐borne parasitic diseases, highly endemic in Iran, and its prevalence is increasing all over the country. Arginase (ARG) activity in isolatedLeishmaniaparasites fromCLpatients is yet to be explored. This study aimed to compare theARGactivity of isolatedLeishmaniapromastigotes fromCLpatients with a standard strain ofLeishmania majorand its influences on the disease pathogenesis. We recruited 16 confirmedCLpatients from Qom Province, in central Iran; after detection ofLeishmaniaspecies usingPCR‐RFLP, we assessed the levels ofARGin the isolated promastigotes and determined the parasites’ growth rate. OnlyL. majorwas identified fromCLpatients. The level ofARGactivity in the isolatedLeishmaniapromastigotes fromCLpatients was significantly higher than that obtained from the standard strain ofL. major. No significant correlations betweenARGactivity and lesion size, number or duration were observed; in contrast, a significant negative correlation was seen betweenARGlevel andLeishmania’growth rate. The obtained results suggest that increasedARGexpression and activity in the isolatedLeishmaniapromastigotes might contribute to the higher parasite infectivity and play a major role in the pathogenicity of theCL.
- 21 July 2017
- Published by Wiley in Parasite Immunology
- Vol. 39 (9)
Arginase activity ofLeishmaniaisolated from patients with cutaneous leishmaniasis
Summary: Cutaneous leishmaniasis (CL) is one of the most important vector‐borne parasitic diseases, highly endemic in Iran, and its prevalence is increasing all over the country. Arginase (ARG) activity in isolatedLeishmaniaparasites fromCLpatients is yet to be explored. This study aimed to compare theARGactivity of isolatedLeishmaniapromastigotes fromCLpatients with a standard strain ofLeishmania majorand its influences on the disease pathogenesis. We recruited 16 confirmedCLpatients from Qom Province, in central Iran; after detection ofLeishmaniaspecies usingPCR‐RFLP, we assessed the levels ofARGin the isolated promastigotes and determined the parasites’ growth rate. OnlyL. majorwas identified fromCLpatients. The level ofARGactivity in the isolatedLeishmaniapromastigotes fromCLpatients was significantly higher than that obtained from the standard strain ofL. major. No significant correlations betweenARGactivity and lesion size, number or duration were observed; in contrast, a significant negative correlation was seen betweenARGlevel andLeishmania’growth rate. The obtained results suggest that increasedARGexpression and activity in the isolatedLeishmaniapromastigotes might contribute to the higher parasite infectivity and play a major role in the pathogenicity of theCL.